TELA Bio launches NIVIS Fibrillar Collagen Pack for surgical wound management

TELA Bio, Inc.

NIVIS is an absorbent matrix of Type I and Type III bovine collagen for moderately to heavily exudating wounds and minor bleeding.
The product complements the OviTex portfolio and expands TELA's soft-tissue preservation offerings.
Commercial launch follows an exclusive development and distribution partnership with Collagen Matrix, Inc. announced in April 2022.
NIVIS is provided in particulate form to be molded and packed into wounds, facilitating contact with host tissue.
Product targets general, plastic, and reconstructive surgery markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.